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according to guidelines?
Osman Savran1, Nina Godtfredsen1,2, Torben Sørensen3,
Christian Jensen4 and Charlotte Suppli Ulrik1,2
Abstract
In a primary care setting, our aim was to investigate characteristics of patients classified as having chronic
obstructive pulmonary disease (COPD) and currently being prescribed inhaled corticosteroids (ICSs). The
electronic patient record system in each participating general practice was searched for patients coded as
COPD (ICPC, Second Edition code R95) and treated with ICS (ACT code R03AK and R03BA, that is, ICS in
combination with a long-acting b2-agonist) or ICS as monotherapy. Data, if available, on demographics,
smoking habits, spirometry, COPD medication, symptom score, blood eosinophils, co-morbidity and
exacerbation history were retrieved from the medical records for all identified cases. Of all patients
registered in the 138 participating general practices, 12.560 (3%) were coded as COPD, of whom 32%
were prescribed ICS. The final study sample comprised 2.289 COPD patients currently prescribed ICS
(98% also prescribed long-acting b2-agonist), with 24% being coded as both COPD and asthma. Post-
bronchodilator spirometry was available in 79% (mean forced expiratory volume in 1 second 60% pred
(standard deviation (SD) 23.3)), symptom severity score in 53% (mean Medical Research Council score 2.7
(SD 1.1)) and 56% of the COPD patients had had no exacerbation in the previous year (and 45% not within the
2 previous years). Blood eosinophils were measured in 67% of the patients. Information on severity of airflow
limitation was missing in 15% of the patients, and the combined information on symptom severity and
exacerbation history was missing in in 46%. Most of the patients (74%) were managed only by their general
practitioner. Although only one-third of the COPD patients were prescribed ICSs, our findings from this study
of a large cohort of patients prescribed ICSs for COPD in general practice suggest that more detailed
assessment of diagnosis and disease characteristics is likely to improve the risk–benefit ratio of maintenance
therapy with ICSs in COPD patients managed in primary care.
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Introduction
Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of mortality world-wide1,2 and is
associated with substantial burden for both the indi-
vidual patient and society.3,4 The aim of maintenance
inhaled therapy for COPD, including treatment with
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inhaled corticosteroids (ICSs), is to relieve symptoms,
reduce risk of exacerbations and improve long-term
outcome.2,5–7 Previous guidelines, or strategy docu-
ments, from the Global Initiative for Chronic Obstruc-
tive Pulmonary Disease (GOLD) proposed ICS for
COPD patients at increased risk of recurrent exacer-
bations. However, the positioning of ICS in the man-
agement of COPD has been much debated recently
based on findings in clinical trials published within
the last few years.8–10 In line with this, in the strategy
paper from GOLD since 2017, ICS is proposed as an
add-on maintenance treatment for COPD patients,
who despite treatment with long-acting bronchodila-
tors, that is, long-acting b2-agonists (LABA) and anti-
muscarinic antagonists (LAMA), still have
exacerbations.11
With increasing awareness of the potential side
effects associated with ICS treatment in COPD
patients including a possible increased risk of pneu-
monia, osteoporosis and diabetes, there has been an
increased focus on identifying COPD patients with a
favourable risk–benefit ratio for treatment with
ICS.11–17
A large sample of patients with COPD from pri-
mary care in Denmark recruited in two previous sur-
veys 1 year apart was examined with regards to
enhancement of adherence to COPD guidelines.18,19
By educating GPs and the general practice staff in the
year between the two surveys, improvements were
observed in the recording of forced expiratory volume
in 1 second (FEV1), FEV1/forced vital capacity (FVC)
ratio, smoking status and Medical Research Council
(MRC) score.18,19 In addition, the general practi-
tioners more often provided advice on smoking cessa-
tion, physical activity and diet and were more likely to
refer patients for pulmonary rehabilitation after the
educational sessions.18 Interestingly, a decline in the
use of ICS to patients with mild COPD was observed
between the two surveys.18,19 In the first survey, 40%
of patients were in monotherapy ICS, and in the sec-
ond survey, 18% of patients were in monotherapy
ICS, suggesting that relatively simple interventions
in general practice may improve adherence to current
guidelines. In an analysis of a large database compris-
ing information on severity of disease, treatment with
bronchodilators, MRC and COPD assessment test
(CAT) score gathered through questionnaires and
electronic patient records by Price et al. revealed that
prescription of maintenance therapy for COPD was
not according to guidelines, as some symptomatic
patients received no treatment, and among those on
maintenance therapy, the majority received ICS irre-
spective of severity of airflow limitation, concomitant
asthma and exacerbation history.20
A more recent study by Chalmers et al. found that
two-thirds of COPD GOLD A and B patients pre-
scribed maintenance therapy within 3 months of diag-
nosis were prescribed ICS-containing treatment.21
Trends over time revealed a decline in initial ICS
prescriptions, but it still accounted for 47% of initial
prescriptions in 2015.
In a large cohort of patients with COPD managed
in primary care, our aim was to explore clinical char-
acteristics of patients currently prescribed ICSs.
Material and methods
The aim was to identify patients coded with a diag-
nosis of COPD in general practice, and thereafter
enrol COPD patients currently being prescribed ICS.
In order to be eligible for the study, the GP had to
fulfil the following criteria: (1) One of the following
Electronic Patient Journal (EPJ) systems: XMO,
Clinea, WinPLC, Ganglion or Novax, and (2) diag-
nostic coding of COPD patients for a minimum of
3 years. Written information about the study as well
as the invitation to participate was distributed to all
interested GPs by the sponsor’s local representative
(during the period 15th August to end of October
2017).
The participating GPs were guided to perform uni-
form searches in their designated EPJ system for the
International Classification of Primary Care, Second
Edition (ICPC-2) code R95 to identify patients with
COPD. Identified COPD patients (ICPC-2 code R95)
currently being prescribed corticosteroids were then
identified through the ATC code R03AK (adrenergics
in combination with corticosteroids) and R03BA (cor-
ticosteroids for inhalation). Search methodology was
provided by the respective EPJ system houses. Search
lists were manually confirmed by participating GPs.
Among patients fulfilling the criteria for inclusion in
the study, 20 patients were selected at random per
clinic, if less than 20 patients were identified, data
were registered for all patients.
All available information on demographics, clini-
cal characteristics, comorbidities, level of blood eosi-
nophils, annual audits and respiratory specialist visits,
prescribed COPD medication, hospital admissions for
COPD, duration of COPD, smoking status and previ-
ous COPD exacerbations were retrieved from the GPs
medical records for each individual patient included
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in the study. The information was anonymized and
entered directly into a secured database. Each patient
registered in the database was assigned a project ID
number. The participating GPs kept record of project
IDs, names and the unique civil registration number
(in Danish called the CPR number).
The present study was a non-drug, non-
interventional study, and approval from the scientific
ethical committee and the Danish Medicines Agency
were, therefore, not mandatory. However, they were
given all relevant study information, and the study
was approved by the Danish Data Protection Agency.
Assessment of COPD severity
According to current guidelines, the severity of
COPD was assessed on the basis of severity of symp-
toms, degree of lung function impairment and exacer-
bation history, provided the information was available
from the GPs medical records.
Degree of dyspnoea and impact of symptoms was
assessed by the MRC scale22 and/or the CAT. Sever-
ity of lung function impairment was assessed by
spirometry and, according to the classifications pro-
vided by GOLD, the patients were classified as either
GOLD1 (FEV1  80% predicted),GOLD2 (FEV1 
50% and < 80% predicted), GOLD 3 (FEV1  30%
and < 50% predicted) or GOLD 4 (FEV1 < 30%
predicted).11
Patients were also classified into four groups, that
is A, B, C and D, following the GOLD 2017 group
classification based on COPD symptoms (more symp-
toms MRC-scale score 2, and/or CAT score 10),
spirometry classification and the number of exacerba-
tions (high risk, two or more exacerbations the previ-
ous year or one hospitalization for COPD
exacerbation).
Data analysis
Statistical analyses were performed using IBM SPSS
version 25 (IBM Corporation, Armonk, New York,
USA). Based on the measurements, the mean values
together with one SD from the mean was calculated.
The original data will be available upon request from
the senior author (CSU).
Results
A total of 12,560 (3%) of 416,233 registered patients
from the 138 participating general practices were
coded with a diagnosis of COPD, of whom 3985 were
currently prescribed ICS and, therefore, eligible for
the present study. Of the eligible patients, 2594
entered the database, with the final cohort comprising
2289 patients (57.4% of the eligible patients), as 304
patients (11.8%) did not fulfil the inclusion criteria (a
diagnosis of COPD and currently prescribed ICS) at
the time of data collection; further details are given in
Table 1 and Figure 1. Characteristics of the included
COPD patients are given in Tables 1 and 2. The GPs
had coded 23.6% of the patients as having both COPD
and asthma.
Assessment of severity of symptoms
The CAT score was not widely used among the parti-
cipating GPs as only 54 patients (0.9% the enrolled
patients) had a registered CAT score (mean score
16.5), whereas 1163 patients had a registered MRC
score (mean score 2.7) (Table 2).
A total of 416,233 patients 
registered in 138 general practices
Patients with a COPD diagnosis (R95) 
12,604 (3%)
AND 
Prescribed Inhaled corticosteroid (ICS)
3,985 (31.6% of COPD patients)
Random selection of max. 20 
patients pr. clinic 
Excluded patients (n = 304):
Re-assessment revealed patients 
not meeting both inclusion criteria.
Final cohort (n = 2,289) with 
COPD diagnosis and current 
treatment with ICS
Patients with COPD registered 
in the database (n = 2,594)
Figure 1. Consort diagram showing the patient selection
procedure.
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Of the enrolled COPD patients included in the
study, 79.7% had information on spirometry in their
medical records and the mean FEV1/FVC was 0.58
(SD 0.15) (Table 2).
The enrolled patients classified according to the
degree of airflow limitation, that is FEV1% predicted,
severity of symptoms and exacerbation history
according to GOLD I to IV and A to D are given in
Figure 2.
Exacerbation history and concomitant therapy
More than half the patients (55.7%) had had no
exacerbation of COPD treated with prednisolone
and/or antibiotics within the last year, and 44.9% had
not had an exacerbation within the last two years
(Figure 3).
Most of the COPD patients were also on LABA
therapy (98.2%), whereas 57.3% were on LAMA
therapy. Most of the patients (74.4%) were managed
only by their GP.
Comorbidities
The most common co-morbidity was cardiovascular
disease (29.4%), followed by osteoporosis (18.9%)
and 23.5% of the enrolled patients were also classified
by the GP as having asthma (Table 3).
Discussion
The present study showed that one-third of patients
classified as having COPD in general practice were on
maintenance therapy with ICSs. Furthermore, more
than two-thirds of the identified COPD patients had
information on post-bronchodilator spirometry in
their medical records, and 24% were classified as
having both COPD and asthma. Our findings suggest
that prescribing ICSs for COPD patients in general
practice may be guided more closely to the clinical
characteristics of the individual patient.
The Danish Health Data Agency (in Danish called
‘Sundhedsdatastyrelsen’) found that two-thirds of all
COPD patients in Denmark received ICS in 2013,
while prescribing ICS had dropped almost 10% 4
years later.23 Simultaneously, a rise in the prescription
rate of long-acting bronchodilators occurred from
one-fifth to one-third.23 Opposed to the findings of
the Danish Health Data Agency, a recent study of a
German COPD cohort found that two-thirds of
patients in GOLD groups A and B were treated with
ICS despite recommendations set by GOLD.2,24
Furthermore, patients in GOLD groups C (18.9 to
21.9% of patients received LABA therapy without a
LAMA) and D (9.2 to 12.2% of patients received
LABA without a LAMA) were undertreated with
long-acting bronchodilators and 3.6% to 6.8% of the
Table 2. Symptom score and lung function in patients with
COPD (n ¼ 2289) identified in general practice currently
prescribed ICSs.
COPD patients,
n ¼ 2289 Missing information
MRC score 49.2%
2 536 (23.4%)
3 627 (27.4%)
CAT score 97.6%
10 35 (1.5%)
>10 19 (0.84%)
Spirometry
FEV1%pred 60.3
a (SD 23.3) 21.3%
FEV1/FVC ratio 0.58
a (SD 0.15) 20.3%
MRC: Medical Research Council; CAT: COPD assessment test;
COPD: chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1 second; %pred: % of predicted value; FVC:
forced vital capacity; SD: standard deviation; ICS: inhaled
corticosteroid.
aMean value.
Table 1. Demographics of the patients with COPD
(n ¼ 2289) identified in general practice currently being
prescribed ICSs.
COPD patients,
n ¼ 2289
Missing
information
(in GPs records)
Sex
Men 1024 (44.7%) –
Women 1265 (55.3%)
Age, years 72a (range 31–102) –
BMI (kg/m2) 27a (SD 6.3) 29.6%
Smoking status 11.8%
Current
smokers
673 (29.4%)
Ex-smokers 1175 (51.3%)
Never-
smokers
171 (7.5%)
Pack-years
(ever
smokers)
39.9 (range 0–150) 61.1%
COPD: chronic obstructive pulmonary disease; ICS: inhaled cor-
ticosteroid; BMI: body mass index.
aMean value.
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patients in these groups received a LABA monother-
apy, despite recommendations by GOLD.2,24
In our study, we have shown that a proportion of
the included COPD subjects (67.4%) have a moderate
blood eosinophil count, while a previous study by
Vedel-Krogh et al. found patients with an increased
risk of exacerbations with a blood eosinophil count
exceeding 0.34 109/L.25 However, results may have
been confounded by patients with undiagnosed
asthma, because only pre-bronchodilator spirometry
measurements were obtained from the included sam-
ple. Compared to the current study, more than two-
thirds of the included patients had information on
post-bronchodilator spirometry.
In the present study, we found that a substantial
proportion of COPD patients prescribed ICS had no
history of recorded exacerbations within the last 2
years, which suggests that ICS are overprescribed for
COPD in primary care managed patients. However,
although information was obtained related to fre-
quency of registered exacerbations and hospital
admissions for COPD in the past 2 years, it should
be emphasized that ICS has been shown to reduce
exacerbation rate in patients with COPD, and by that
some patients may have lower exacerbation rate than
previously due to benefit from ICS therapy. Some
further limitations should be emphasized in the cur-
rent study. Consultations and prescriptions in primary
Figure 2. Classification of enrolled subjects with COPD on ICS therapy (n ¼ 2289) according to GOLD. (a) Upper panel
based on symptom severity and exacerbation history (as recorded in the GPs medical records) and (b) lower panel
according to degree of airflow limitation. COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for
Chronic Obstructive Pulmonary Disease; ICS: inhaled corticosteroid.
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care may not be sufficient to validate an exacerbation
and the records provided by the GPs for the current
study may, therefore, have over- or underestimated
exacerbation rate in the included COPD patients. On
the other hand, the individual participating patients
GP have direct access, when the patient is in the con-
sultation room, to information on filled prescriptions
(through the so-called ‘Fælles Medicinkort’). The
included COPD patients had, overall, moderate to
severe airflow limitation, which may be related to the
relatively high age of the patients.26 Another limita-
tion was that EPJs did not, as may be expected,
contain all relevant information on characteristics of
the COPD patients, and, in line with this, we may
have missed some important details because of
missing information. However, by studying
subgroups of COPD, we may reduce inconsistency
for some endpoints, such as blood eosinophil count
in future analyses. Lastly, the relatively frequent
missing information on dyspnoea, lifetime tobacco
exposure and blood eosinophils may limit our possi-
bilities for more complex statistical analysis, but
nevertheless, the present study provides important
insight into the characteristics of COPD patients
managed in primary care.
The present study investigated characteristics of
patients with COPD prescribed ICS in primary care
and showed that ICS seems to be prescribed for
COPD across the whole spectrum of disease severity
and clinical characteristics. Our findings, therefore,
0 500 1000 1500 2000 2500
COPD hospitalizaons within the last 2 years
COPD hospitalizaons within the last year
COPD exacerbaons within the last 2 years
COPD exacerbaons within the last year
Corcosteroids for COPD exacerbaons (minimum of 3 days)
within the last 2 years
Corcosteroids for COPD exacerbaons (minimum of 3 days)
within the last year
Anbiocs for respiratory infecons (minimum of 3 days)
within the last 2 years
Anbiocs for respiratory infecons (minimum of 3 days)
within the last year
FREQUENCY
N=0 N=1 N>1
Figure 3. Hospital admissions for exacerbations, rescue courses of oral corticosteroids and antibiotics for exacerbations
in COPD patients (n ¼ 2289) currently prescribed ICSs (n ¼ 0 exacerbations, n ¼ 1 exacerbation and n > 1 exacerba-
tions). COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid.
Table 3. Presence of co-morbiditiesa in COPD patients (n ¼ 2289) currently prescribed ICSs managed in primary care.
COPD patients, n ¼ 2289 Yes No Missing information (n)
Type 2 Diabetes 387 (16.9%) 1901 (83.0%) 1
Cardiovascular disease 673 (29.4%) 1615 (70.6%) 1
Depression 311 (13.6%) 1976 (86.3%) 2
Osteoporosis 433 (18.9%) 1843 (80.5%) 13
Anxiety 207 (9.0%) 2079 (90.8%) 3
Asthma 539 (23.5%) 1747 (76.3%) 3
COPD: chronic obstructive pulmonary disease; ICS: inhaled corticosteroid.
aAccording to the GPs medical record for each individual patient.
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may indicate that management of COPD patients in
general practice may be tailored more precisely to the
characteristics of the individual patient, and by that,
improve risk–benefit ratio, not least regarding treat-
ment with ICSs.
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